Drug-Eluting Stents vs Bare-Metal Stents: What Has Changed in Heart Treatment

What Is a Stent — and Why Do You Need One?

When a coronary artery becomes narrowed or blocked by plaque, blood flow to the heart muscle is reduced. This can cause chest pain (angina) or, in serious cases, a heart attack. One of the most common and effective ways to restore that blood flow is a procedure called percutaneous coronary intervention (PCI), commonly known as angioplasty.

During PCI, a cardiologist threads a thin, flexible tube (catheter) through a blood vessel — usually in the wrist or groin — up to the blocked artery. A small balloon is inflated to open the blockage. Then, a small mesh tube called a stent is placed inside the artery to keep it open.

Stent technology has come a long way since the first stents were used in the 1980s. Understanding the difference between the two main types — bare-metal stents (BMS) and drug-eluting stents (DES) — can help you have a more informed conversation with your cardiologist.

---

Bare-Metal Stents: Where It All Began

A bare-metal stent is exactly what the name suggests — a small, metallic mesh scaffold, typically made of stainless steel or cobalt-chromium alloy, with no coating or medication on it.

When BMS were introduced in the late 1980s and became widely used through the 1990s, they were a significant step forward. Before stents, angioplasty with a balloon alone often caused the artery to close back up — a problem called acute recoil. The stent solved that by physically holding the vessel open.

The Problem: Restenosis

However, bare-metal stents came with their own challenge: in-stent restenosis. When a stent is placed inside an artery, the body recognises it as a foreign object. In response, smooth muscle cells begin to grow inside the stent — a process called neointimal hyperplasia. Over time, this new tissue can re-narrow the artery, causing symptoms to return.

Studies showed that restenosis occurred in roughly 20–30% of patients who received bare-metal stents within six to twelve months. This meant that a significant number of patients needed a repeat procedure.

---

Drug-Eluting Stents: A Major Step Forward

To tackle the restenosis problem, researchers developed drug-eluting stents. These stents have the same basic metallic structure as bare-metal stents, but they are coated with a polymer that slowly releases a medication directly into the artery wall over several weeks to months.

The drugs most commonly used — such as sirolimus, everolimus, zotarolimus, or paclitaxel — work by suppressing the excessive cell growth that causes restenosis. By delivering medication right where it is needed, DES dramatically reduced the restenosis rate.

How Much of a Difference Do They Make?

Clinical trials and large-scale real-world data consistently show that drug-eluting stents reduce in-stent restenosis rates to 5–10% or even lower — a substantial improvement over bare-metal stents. This means fewer patients need a repeat angioplasty or bypass surgery.

First-generation DES (introduced in the early 2000s) were very effective at preventing restenosis, but raised concerns about a rare but serious complication called late stent thrombosis (a blood clot forming in the stent, months or even years later). This was partly linked to the thicker, more durable polymer coatings used.

---

The Evolution: Second- and Third-Generation DES

Stent manufacturers responded to these concerns with continued innovation:

• Thinner stent struts — thinner metal means less injury to the artery wall and faster healing.
• Biocompatible or biodegradable polymers — newer polymers are less likely to cause inflammation and dissolve over time, reducing the long-term risk of clot formation.
• Improved drug formulations — more precise, lower doses of medication that are effective with fewer side effects.

Second-generation DES (such as everolimus-eluting and zotarolimus-eluting stents) have become the standard of care in most cardiac catheterisation laboratories, including those in Rajkot and across Gujarat. They offer the restenosis-reduction benefit of first-generation DES with a significantly improved safety profile.

Some centres now also use bioresorbable scaffolds (BRS) — stents made from a material that dissolves completely over two to three years, leaving nothing permanent behind. While this concept is promising, ongoing research is still defining which patients benefit most from this approach.

---

Drug-Eluting Stent vs Bare-Metal Stent: A Side-by-Side Look

Feature	Bare-Metal Stent	Drug-Eluting Stent
Restenosis rate	~20–30%	~5–10% or lower
Medication coating	None	Yes (sirolimus, everolimus, etc.)
Dual antiplatelet therapy (DAPT) duration	Typically 1 month	Typically 6–12 months (or longer)
Risk of late stent thrombosis	Lower (older data)	Very low with modern DES
Recommended for most patients today	Less common	Preferred in most cases

What About Blood-Thinning Medicines?

One practical difference between the two stent types is the required duration of dual antiplatelet therapy (DAPT) — a combination of two blood-thinning medicines (usually aspirin plus clopidogrel or ticagrelor). These medicines prevent blood clots from forming while the stent heals into the artery wall.

• With bare-metal stents, DAPT is typically needed for about one month.
• With drug-eluting stents, DAPT is usually continued for six to twelve months, sometimes longer depending on individual risk factors.

This is an important consideration. For example, if a patient needs to undergo an unrelated surgery soon after their stent procedure, the cardiologist may weigh the shorter DAPT requirement of a BMS. However, for the vast majority of patients, the restenosis benefit of a DES outweighs this consideration, and modern DES guidelines allow for shorter DAPT durations in selected low-risk patients.

---

Who Gets Which Type of Stent Today?

In current clinical practice, drug-eluting stents are preferred for most patients undergoing coronary angioplasty. International cardiology guidelines — including those from the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) — recommend DES over BMS for the majority of clinical situations.

Bare-metal stents may still occasionally be considered in very specific circumstances, such as:

• Patients who cannot tolerate prolonged DAPT due to a very high risk of bleeding
• Certain clinical or anatomical situations as judged by the treating cardiologist

To illustrate with a general example: a 58-year-old with a single blocked coronary artery and no contraindications to blood thinners would, in most cases today, receive a modern drug-eluting stent. This gives the lowest possible chance of needing a repeat procedure in the coming years.

Cardiologists in Rajkot and across India follow the same evidence-based protocols, ensuring patients have access to the same advances in stent technology seen globally.

---

What to Expect After Your Stent Procedure

Regardless of which stent type is used, recovery from PCI is generally straightforward:

• Most patients are discharged within 24–48 hours.
• You will be prescribed blood-thinning medications — take them exactly as directed and never stop without consulting your cardiologist.
• Lifestyle changes — a heart-healthy diet, regular gentle activity, quitting smoking, and managing blood pressure and diabetes — are equally important in ensuring long-term success.
• Regular follow-up visits are essential to monitor your recovery.

---

Key Takeaways

• A stent is a small mesh tube placed inside a blocked coronary artery to keep it open after angioplasty.
• Bare-metal stents were a breakthrough in the 1990s but had a significant restenosis (re-narrowing) rate of 20–30%.
• Drug-eluting stents release medication to suppress cell overgrowth, reducing restenosis to 5–10% or lower.
• Modern second-generation DES are safer than earlier versions, with very low rates of late clot formation.
• DES are now the standard recommendation for most patients in guidelines followed worldwide, including in Rajkot and Gujarat.
• DAPT (dual antiplatelet therapy) duration differs between stent types and must be followed carefully.
• Lifestyle changes after any stent procedure are just as important as the technology used.

---

If you or a loved one has been advised a stent procedure or has questions about which type of stent is right for your situation, consider speaking with a qualified interventional cardiologist. Dr. Nikhila Pachani's clinic in Rajkot, Gujarat, is available to guide you through your options with clarity and personalised care — book a consultation today.